SUZHOU, China, Jan. 20, 2020 /PRNewswire/ -- TenNor Therapeutics, a clinical-stage, global biopharmaceutical company has received FDA Orphan Drug Designation for TNP-2092 to treat prosthetic joint infections.

Medical devices such as prosthetic joints, central venous catheters and artificial heart valves are being used more frequently and biofilm infections associated with them have become a major challenge. Biofilm infections are extremely hard to treat and often require surgical intervention plus prolonged antibiotic therapy, leading to high cost and major impact to patient's quality of life. TNP-2092 is a multitargeting drug conjugate, exerting antibacterial activity by inhibiting three essential targets in bacterial biofilms: RNA polymerase, DNA gyrase and topoisomerase IV. TNP-2092 has demonstrated strong bactericidal activity, low frequency for development of resistance and an excellent safety profile. TNP-2092 has shown better efficacy than standard of care in a variety of animal models of bacterial biofilm infections.

TenNor has previously received FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations for TNP-2092. Recently, TenNor has completed a Phase II clinical trial for TNP-2092 in the United States for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and received positive results.

About TenNor Therapeutics

TenNor Therapeutics is a clinical-stage company specialized in the discovery and development of differentiated new drug products in diseases associated with bacterial infection and metabolism. TenNor possesses a unique multi-targeting drug conjugate technology platform and a strong new drug development pipeline with global IP protection. Several products are currently in late stage of clinical development, targeting H. pylori infection, implanted medical device infections, hepatic encephalopathy and irritable bowel syndrome with diarrhea. The company is committed to address the unmet needs in the disease area and provide safe and effective therapies for patients in China and around the world.

For more information, please visit: www.tennorx.com